Exercise improves walking and thinking
- Trial ID
- NCT07478146
- Official Title
- Effects of Aerobic Training on Cerebrovascular Function, Cognitive Performance and Gait Parameters in Patients With Parkinson's Disease: A Randomized Controlled Trial
- Goal
- Exercise improves walking and thinking
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Raphael Mendes Ritti Dias
- Study Type
- INTERVENTIONAL
- Enrollment
- 40 participants
- Conditions
- PARKINSON DISEASE (Disorder)
- Interventions
- Aerobic training, Usual Care
Plain-Language Summary
Researchers are testing whether regular moderate-intensity aerobic exercise can improve brain blood flow, thinking, and walking in people with Parkinson's. Participants do supervised aerobic workouts that raise the heart rate into a moderate zone to boost cerebrovascular reactivity and brain oxygen delivery, which may support cognitive performance and gait; the program is compared with usual care and is meant to complement, not replace, medications like levodopa. The trial is looking for adults 40 and older with Parkinson's at Hoehn and Yahr stages 1 to 3, who can walk independently, have a MoCA score of 18 or higher, have been on stable antiparkinsonian medication for at least four weeks, and are medically cleared for moderate exercise.
Locations
- Associação Brasil Parkinson, São Paulo, São Paulo, Brazil
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Aerobic training. Researchers are testing whether regular moderate-intensity aerobic exercise can improve brain blood flow, thinking, and walking in people with Parkinson's. Participants do supervised aerobic workouts that raise the heart rate into a moderate zone to boost cerebrovascular reactivity and brain oxygen delivery, which may support cognitive performance and gait; the program is compared with usual care and is meant to complement, not replace, medications like levodopa. The trial is looking for adults 40 and older with Parkinson's at Hoehn and Yahr stages 1 to 3, who can walk independently, have a MoCA score of 18 or higher, have been on stable antiparkinsonian medication for at least four weeks, and are medically cleared for moderate exercise.
- Who can participate?
- Participants must be at least 40 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 1 year and 4 months.